Online citations, reference lists, and bibliographies.
← Back to Search

Echocardiographic Surveillance For Asymptomatic Late‐onset Anthracycline Cardiomyopathy In Childhood Cancer Survivors

Ibraheem F Abosoudah, Mark L. Greenberg, K. Ness, Lee Benson, P. Nathan
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The optimal frequency of echocardiographic surveillance in asymptomatic childhood cancer survivors exposed to anthracyclines has not been established. We evaluated the effectiveness of performing surveillance echocardiograms according to the Children's Oncology Group's (COG) Long‐Term Follow‐Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers in survivors ≥1 year from concluding therapy.
This paper references
10.1200/JCO.2009.26.5751
Cardiotoxicity after childhood cancer: beginning with the end in mind.
S. Lipshultz (2010)
Survival analysis using the SAS system : a practical guide
Paul D. Allison (1995)
10.1136/bmj.b4606
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
D. Mulrooney (2009)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
10.1159/000207614
Long-term follow-up of survivors of childhood cancer.
A. Edgar (2009)
seer data submission, posted to the seer web site
(1975)
10.5555/URI:PII:009377549290207H
The cardiotoxicity of chemotherapeutic drugs.
A. Allen (1992)
10.1002/pbc.20358
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients
B. Anderson (2005)
10.1200/JCO.2004.11.032
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.
W. Landier (2004)
10.1056/NEJMoa0810613
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
G. Perilongo (2009)
10.1002/14651858.CD005006.pub3
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2006)
10.3109/07357909909021433
Cardiotoxicity of cancer therapy.
K. Tolba (1999)
10.1056/NEJM199103213241205
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
S. Lipshultz (1991)
10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2
A clinicopathologic analysis of adriamycin cardiotoxicity
E. Lefrak (1973)
10.1200/JCO.2004.06.022
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.
J. Silber (2004)
10.1111/j.1365-2141.2005.05759.x
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
Karlijn A Wouters (2005)
10.1001/JAMA.1991.03470120074036
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
10.1200/JCO.2001.19.1.191
Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.
L. Kremer (2001)
10.1200/JCO.2001.19.7.1926
Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.
D. Green (2001)
10.1093/ANNONC/MDF167
Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.
L. Kremer (2002)
10.1200/JCO.2005.12.121
Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
S. Lipshultz (2005)
10.1161/01.HYP.34.2.236
Validity of echocardiographic measurement in an epidemiological study. Project HeartBeat!
S. Dai (1999)
10.1200/JCO.2002.12.102
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
S. Lipshultz (2002)
10.1056/NEJM199506293322602
Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
S. Lipshultz (1995)
10.1093/ejechocard/jen242
Normalization of echocardiographically derived paediatric cardiac dimensions to body surface area: time for a standardized approach.
J. Kaski (2009)
10.1200/JCO.1995.13.7.1546
Cardiac function in Wilms' tumor survivors.
K. Sørensen (1995)
Long term follow up of survivors of childhood cancer: Guideline no. 76. Scottish Collegiate Guidelines Network (SIGN)
10.1016/0305-7372(93)90036-Q
Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.
A. P. Launchbury (1993)
Therapy based long term follow up: Practice statement
(2005)
10.1198/tech.2001.s617
Categorical Data Analysis Using The SAS1 System
M. Stokes (1995)
10.1017/S1047951109990862
Reliability of echocardiographic measurements of left cardiac structures in healthy children.
M. Geelhoed (2009)
Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Children's Oncology Group
(2009)
10.1016/j.ejca.2008.11.042
Survival of European children and young adults with cancer diagnosed 1995-2002.
G. Gatta (2009)



This paper is referenced by
10.1002/cncr.26481
Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline‐induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions
R. Watts (2012)
10.1053/j.seminoncol.2013.09.010
Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management.
Richard M. Steingart (2013)
10.1186/s40959-018-0032-3
Tissue Doppler Imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer
F. Venturelli (2018)
10.1016/j.jaccao.2019.10.008
Symptomatic Heart Failure in Acute Leukemia Patients Treated With Anthracyclines
Y. Kang (2019)
10.1002/pbc.24498
Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective
E. Orgel (2013)
10.1089/jayao.2017.0024
Racial Differences in 20-Year Cardiovascular Mortality Risk Among Childhood and Young Adult Cancer Survivors.
A. Berkman (2017)
10.1016/S1470-2045(14)70409-7
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
S. Armenian (2015)
10.1200/JCO.2015.61.5187
Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
E. A. M. Feijen (2015)
10.1186/s12885-017-3505-0
Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study
Amy Skitch (2017)
10.1002/pbc.25651
Echocardiographic Detection of Cardiac Dysfunction in Childhood Cancer Survivors: How Long Is Screening Required?
A. Ramjaun (2015)
10.1016/j.clinbiochem.2013.06.029
Growth-differentiation factor-15 and tissue doppler ımaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors.
D. Arslan (2013)
KNOWLEDGE OF DIAGNOSIS, TREATMENT AND LATE EFFECTS IN ADOLESCENT AND YOUNG ADULT SURVIVORS OF CHILDHOOD AND ADOLESCENT CANCER
I. A. Syed (2013)
10.1161/JAHA.115.001891
Treatment, Behavioral, and Psychosocial Components of Cardiovascular Disease Risk Among Survivors of Childhood and Young Adult Cancer
A. Berkman (2015)
10.1002/pbc.26367
Yield of screening echocardiograms during pediatric follow‐up in survivors treated with anthracyclines and cardiotoxic radiation
Michael B Spewak (2017)
10.1007/s11764-020-00965-w
Adherence to cardiomyopathy screening guidelines among adolescent and young adult cancer survivors exposed to chest radiation and/or anthracyclines
Hilary C. Tanenbaum (2020)
10.1007/978-3-319-16435-9_10
Cardiovascular Effects of Cancer Therapy
D. Briston (2015)
Semantic Scholar Logo Some data provided by SemanticScholar